Clinical trial
A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II
NCT01412164 is registered in ClinicalTrials.gov with Shanghai MicroPort Medical (Group) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- August 31, 2011
- Completion date
- January 31, 2017
- Enrollment
- 730 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.